BUSINESS WIRE

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

Loading media player...
Professor Clifford J Bailey Professor of Clinical Science, Life and Health Sciences University of Aston, UK

Embed